She said "early on" everyone assumed Covid would be straightforward, instead of presenting so differently (lungs, clotting/stroke, heart issues, liver, kidney, pancreas, gastrointestinal, etc) for different people, ages, etc. Back last April when CD12 was given the green light, both the FDA and Cytodyn ostensibly believed that would be an ample size. She just said that the FDA now knows that's not enough. Hindsight, basically.

Quote:

---

Woodcock just said studies with monoclonal with 400 patients were not going to be enough. Why would Cytodyn even do a study that would not be accepted to begin with?

Read More: https://investorshangout.com/post/view?id=608...z6pOsSZCmC

---